Benchmark Reaffirms “Speculative Buy” Rating for Nephros (NASDAQ:NEPH)

Nephros (NASDAQ:NEPH)‘s stock had its “speculative buy” rating reissued by equities researchers at Benchmark in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock. Benchmark’s price objective indicates a potential upside of 206.75% from the stock’s current price.

Nephros Stock Down 0.6 %

NASDAQ:NEPH opened at $1.63 on Tuesday. Nephros has a 52-week low of $1.36 and a 52-week high of $4.04. The business’s 50-day moving average price is $1.62 and its 200 day moving average price is $1.93. The firm has a market cap of $17.18 million, a P/E ratio of -18.11 and a beta of 1.19.

Institutional Trading of Nephros

An institutional investor recently bought a new position in Nephros stock. Dimensional Fund Advisors LP acquired a new stake in shares of Nephros, Inc. (NASDAQ:NEPH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 17,631 shares of the company’s stock, valued at approximately $37,000. Dimensional Fund Advisors LP owned about 0.17% of Nephros as of its most recent filing with the Securities and Exchange Commission. 41.10% of the stock is owned by institutional investors and hedge funds.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.